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Abstract
Background: Chronic fatigue syndrome (CFS) is a disease of unknown aetiology. A patient with
CFS had unexpected, marked recovery of CFS symptoms lasting for five months during and after
cytotoxic chemotherapy for Hodgkin's disease. We reasoned that the transient CFS recovery was
related to methotrexate treatment, which induces immunomodulation in part through B-cell
depletion.
Methods: In a case series, this patient and two additional CFS patients were B-cell depleted by
infusion of the monoclonal anti-CD20 antibody rituximab.
Results: All three had improvement of all CFS symptoms. Patients 1 and 2 had major amelioration
from 6 weeks after intervention, patient 3 slight improvement from the same time, but then
improved markedly from 26 weeks after intervention. The symptomatic effect lasted until weeks
16, 18 and 44, respectively. At relapse, all were retreated with a single (patient 1) or double
rituximab infusion (patients 2 and 3). Again, all three had marked symptom improvement,
mimicking their first response. After new symptom recurrence, patients 1 and 2 were given weekly
oral methotrexate, patient 1 having effect also from this agent. Patients 1 and 2 were again treated
for a third rituximab infusion after new relapse, again with a marked clinical benefit. No unexpected
toxicity was seen.
Conclusion: These observations suggest that B-lymphocytes are involved in CFS pathogenesis for
a subset of patients. Benefit for all CFS symptoms, the delayed symptom relief following B-cell
depletion, the kinetics of relapses, and the effect also from methotrexate treatment, provide
suggestive evidence that B-cells play a significant role in the ongoing clinical features, and that CFS
may be amenable to therapeutic interventions aimed at modifying B-cell number and function. More
systematic investigations of this therapeutic strategy, and of its biological basis, are now needed.
Background
Chronic fatigue syndrome (CFS) has gradually gained rec-
ognition as a clinical entity. The diagnosis is clinical and
based on a number of major and minor symptoms [1].
The main criterion is unexplained severe fatigue, without
proper alleviation by rest, lasting at least 6 months, and
resulting in a substantial reduction in occupational,
social, and personal activities. Excessive post-exercise
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exhaustion, sleep disturbances, muscle and joint pain,
headaches and cognitive disturbances with concentration
or memory problems are frequent. Bowel symptoms, tem-
perature regulation dysfunction, postural hypotension,
and hypersensitivity to noise and light are often described.
The entity is a major public health problem, estimated to
affect approximately 0.2 – 0.4% of the population [2]. No
clear pathogenesis has been found, but both host and
environmental factors are presumed to interact. Hypothe-
ses include persisting viral infections, immune system
dysfunction, neurological disease, neuroendocrine disor-
der, metabolic or autonomic disturbances, ion channel
dysfunction, and exposure to toxins or vaccinations [3].
One of the most focused theories is immune deregulation,
and alterations in immune cell subsets and their relative
numbers have been reported [4]. We have recently
observed and treated a patient, with a resulting new line
of research on CFS. Her case story resulted in a double-
blinded, randomized and placebo-controlled study of
drug intervention in CFS, which is recruiting
(NCT00848692). Here we report the initial experiences
from this patient and two additional pilot CFS patients, in
the preparatory phase for the randomized study. The
results may yield clues to disclose the pathogenesis of CFS
and to develop effective treatment.
Case history
The patient, born in 1964, had previously had thyroiditis
and was substituted with thyroxin. She developed CFS
shortly after mononucleosis in 1997, with severe fatigue,
headaches, muscle and skin pain, sleep disturbance and
major concentration problems. The condition was stable
when she was diagnosed with classic Hodgkin's disease
(Stage IIA) in 2003 and given 4 courses of chemotherapy
with the ABVD regimen [5], thereafter involved field radi-
ation (30,6 Gy). At recurrence of the malignancy in 2004,
she was given 4 courses of chemotherapy with the MIME
regimen (methotrexate, ifosfamide, methyl-GAG and
etoposide) [6] as preparation for possible high dose
chemotherapy. Between the first and second MIME
courses (4–5 weeks after start of chemotherapy), the
patient unexpectedly started a remarkable recovery from
all CFS symptoms and experienced increasing energy. She
started to take long walks. Pain decreased significantly
and cognitive functions improved. This period of
improvement and impressive increase in quality of life
lasted 4–5 months (about 3 months after the last MIME
cycle) before the CFS symptoms all showed a gradual
return. In 2006 she was treated for a second lymphoma
recurrence, with dose-escalated BEACOPP chemotherapy
[7], followed by high-dose chemotherapy (BEAM regi-
men) with autologous stem cell transplantation. She has
since been recurrence free from the lymphoma. The CFS
symptoms were present without noticeable improvement
after the stem cell transplantation. The symptomatic relief
experienced by the patient following MIME chemother-
apy was the only significant improvement she had experi-
enced during her 10-year history of CFS.
The aetiology of CFS is at present unknown, but a prevail-
ing hypothesis is a chronically deregulated and activated
immune system, with altered central nervous system func-
tioning [4]. Among the reported immunological abnor-
malities in CFS, an increased Th2-type immune response
was demonstrated [8], and some studies have shown an
increase in number of CD20+ CD5+ B-lymphocytes [9-
11]. The MIME chemotherapy regimen contains meth-
otrexate (Mtx) in moderate doses (30 mg/m2 intrave-
nously every third week). Based on the observed clinical
benefit on CFS symptoms in this patient from MIME, the
lack of improvement from the three other chemotherapy
regimens, and the known (but poorly understood) immu-
nomodulatory effects of low-dose weekly Mtx treatment
in e.g. rheumatoid arthritis, we speculated that the
observed clinical improvement was related to Mtx. One of




The above-mentioned patient treated for lymphoma, and
later two other patients with established CFS, were offered
B-cell depletion therapy after being thoroughly informed
of the experimental approach. Especially the unknown
tolerance of the investigational drug in CFS patients, and
that some reports indicate that a subset of patients may
have an ongoing viral infection [13,14] were emphasized.
After response was seen in the first patient, the concept
was discussed with the chairman of the Regional Ethical
Committee, and permission was given for open-label
treatment of two additional patients while awaiting the
formalities of a planned randomized study. This study
(NCT00848692) has been approved by the Regional Eth-
ical Committee in Norway (200800657-6/MRO/400) and
is recruiting. Written consent was obtained from the three
patients for treatment and for publication of this case
series.
Pretreatment evaluation
The patients were previously diagnosed with CFS at the
Department of Neurology at Haukeland University Hos-
pital, and had disabling and relatively stable CFS. To
exclude other diseases associated with fatigue, standard
laboratory blood tests, serology for relevant viruses, endo-
crine function tests, and presence of serum autoantibodies
were analyzed. Serum electrophoresis, quantifying of
immunoglobulins, and immune phenotyping of lym-
phocytes were performed. All had normal brain MRIs.BMC Neurology 2009, 9:28 http://www.biomedcentral.com/1471-2377/9/28
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Drug intervention
B-cell depletion was performed by initially giving a single
dose of the monoclonal mouse-human chimeric anti-
CD20 antibody rituximab (MabThera®, Roche) 500 mg/
m2 (max dose 1000 mg) intravenously. After oral cetirizin
10 mg, dexamethason 8 mg and paracetamol 1 g, rituxi-
mab 2 mg/ml was infused under nurse surveillance,
according to local practice. Retreatment was offered with
the same regimen and dosage in patient 1 (with reduced
bone marrow function after high dose chemotherapy for
lymphoma), or 500 mg/m2 (max dosage 1000 mg) for
two infusions two weeks apart (patients 2 and 3). Patients
1 and 2 were also given oral Mtx once weekly at recurrent
symptoms after the second rituximab round (Figure 1).
Follow-up
Rituximab infusions were uncomplicated and the patients
were dismissed from hospital the day after treatment.
They were seen at the oncology outpatient department at
1-2 month intervals and had telephone contact with the
researchers every 1–2 week. The patients were asked to
keep a written track of all symptom development after the
intervention. There were no clinical interventions during
follow-up, other than those documented in this article,
that could explain the symptom development during fol-
low-up.
Funding source
This case series was exclusively supported by Haukeland
University Hospital.
CFS symptoms during follow-up of three patients after first rituximab infusion Figure 1
CFS symptoms during follow-up of three patients after first rituximab infusion. The patients had regular consulta-
tions with 1–2 month intervals, and telephone contact with 1–2 week intervals for the follow-up period. The patients kept 
record of their symptom development and assessed this figure, to assure that the joint interpretation of the two investigators 
was in accordance with their opinion. In each patient all CFS symptoms in general changed synchronously, thus the overall 
symptom status was subjectively scored from 1 (no symptoms) to 10 (severe symptoms) on the vertical scale. Below the figure 
B-cell numbers in peripheral blood are shown, for each patient, and plotted at the appropriate time during follow-up (i.e. 
weeks from first rituximab infusion). R: rituximab infusion. M: start of oral weekly methotrexate.
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Results
The laboratory investigations performed prior to treat-
ment did not uncover any concomitant disease. All labo-
ratory tests for serum autoantibodies were negative, except
for elevated titres of thyroid anti-microsomal antibodies
in patient 1. All three patients had positive IgG, but nega-
tive IgM, to Epstein-Barr virus (EBV) and cytomegalovirus
(CMV). Serologic tests for EBV and CMV, and in addition
PCR analyses, were repeated during follow-up, without
any evidence of active infection. The serum levels of IgG
were slightly reduced from inclusion to the end of follow-
up (12.1 - 5.8, 9.5 - 8.5, 12.5 - 11.6 g/L for patients 1, 2,
and 3, respectively, normal range 6.0 – 15.3 g/L).
Patient 1
The patient with a transient improvement of symptoms
during MIME chemotherapy for Hodgkin's disease had
profound fatigue with little rest relief before rituximab
infusion. She was mostly indoors and could only take
walks for a few minutes, and had marked, diffuse muscle
and skin pain. Sleep disturbances and cognitive dysfunc-
tion were profound. The first five weeks after rituximab
she noted absolutely no change. From six weeks after
treatment she started to experience increasing energy. The
following weeks her condition improved substantially,
she was able to take walks for up to two hours duration,
and needed shorter periods of rest. Muscle and skin pain
decreased markedly. Cognitive function improved sub-
stantially, and the sleep quality turned normal. However,
from 14 weeks after the single rituximab infusion, her
condition started to deteriorate, with gradually increasing
fatigue, muscle and skin pain, cognitive dysfunction, and
the sleep disturbances reappeared (Figure 1). Five months
after the first rituximab infusion, she again had stable and
disabling CFS symptoms, although she was still better
than before the intervention. She insisted on retreatment
and 20 weeks after her first treatment, she was given a new
single infusion of rituximab at the same dosage. After six
weeks, she again experienced a gradual recovery from all
CFS symptoms (fatigue, pain, cognitive symptoms, sleep)
with a major effect on quality of life. After the second infu-
sion, the therapeutic effect was maximal at 12–16 weeks
(32–36 weeks from the first infusion), with slow symp-
tom worsening thereafter (Figure 1).
We then decided to start weekly oral methotrexate (Mtx)
from 19 weeks after the second rituximab-infusion, at a
time point when she did not have detectable CD19+ B-
cells in peripheral blood. Mtx was started at one dose of
7,5 mg per week, and increasing to 12,5 mg per week dur-
ing the next two months. From 10 weeks after onset of
weekly Mtx, she has again experienced gradual recovery
from CFS symptoms. She used Mtx for 25 weeks and
reported significant improvement. Symptom recovery was
slower with Mtx than rituximab. However, slow worsen-
ing resumed from 26 weeks after start of Mtx (Figure 1).
She was again treated with a new (third) rituximab infu-
sion at the same dosage, with ongoing weekly Mtx (35
weeks after start of Mtx treatment). At this time point B-
cells in peripheral blood were increasing (Figure 1). In
line with her experiences from the previous interventions,
she had a major improvement of all CFS related symp-
toms, again starting from 6 weeks after the rituximab
treatment (Figure 1).
Patient 2
A 34-year-old male encountered CFS in 2000 after infec-
tious mononucleosis. At the same time, diabetes type I
was diagnosed. In 2005 he was treated for a testicular sem-
inoma Stage IIA with orchidectomy and postoperative
radiation therapy and has since been recurrence free. Since
2000 he was completely unable to work. Most days he was
only able to perform minor in-house tasks. He had severe
general myalgic pain, headaches, chronic diarrhoea,
increased sweating and dizziness. Cognitive function was
markedly reduced and worsening over the years. He was
unable to read more than a page or two of writing and suf-
fered from hypersensitivity to noise.
Two weeks after single rituximab infusion (500 mg/m2)
the diarrhoea vanished, while all the other symptoms
remained unchanged. Before treatment he was mostly
confined to rest indoors, with very brief walks, usually to
and from the garden mailbox once daily. However,
approaching six weeks after treatment he started to feel
energy. During the next two weeks his activity level and
muscle usage increased to the greatest level since the CFS
debut. He could take one-hour walks and started to do
carpentry on his house. Myalgic pain was markedly
reduced. Cognitive functions improved remarkably, and
he could now read a whole book without interruption.
The hypersensitivity to noise decreased. He and his wife
confirmed that family life had improved considerably.
The clinical benefit was most pronounced until 12 weeks
after the rituximab infusion, thereafter all CFS symptoms
started to gradually incline. At 18 weeks after the interven-
tion, he described symptoms as almost equal to baseline
(Figure 1). He was then retreated with two infusions of
rituximab 1000 mg, given two weeks apart. As following
the first treatment, he started to recover first from diar-
rhoea (after 3 weeks). Then, after six weeks, he reported
less cognitive symptoms and days later the fatigue started
to improve.
The double rituximab infusion gave a clear CFS symptom
improvement most prominent 16 weeks after the infu-
sion. Thereafter, he has experienced a very slow increase in
symptoms. However, six months after the infusion, he
still had some clinical response. Fifty weeks after the firstBMC Neurology 2009, 9:28 http://www.biomedcentral.com/1471-2377/9/28
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rituximab infusion (30 weeks after the second) he started
treatment with weekly oral Mtx. At the time points of the
second rituximab treatment (week 19) and of Mtx initia-
tion (week 50) he did not have detectable CD19+ B-lym-
phocytes in peripheral blood. After 12 weeks on weekly
oral Mtx (62 weeks after first intervention) he still did not
experience symptom amelioration, and was then given a
new double rituximab infusion (each of 1000 mg) two
weeks apart, with ongoing Mtx treatment. At this time the
B-cell number increased (Figure 1). In accordance with
the previous courses, he after eight weeks (week 70) again
had a marked improvement of fatigue, cognitive function,
muscle pain, dizziness, noise intolerance, sweating and
diarrhoea (Figure 1).
Patient 3
The 23-year-old school pupil attained CFS following
infectious mononucleosis in 2001. School activities had
slowed to the extent that she was in her sixth year of a
three-year program. Marked reduction in physical activity
and only moderate relief from rest, diffuse muscle pain
and diarrhoea were present. Cognitive dysfunction was
moderate. She felt frustrated as a consequence of the dis-
ease and its negative impact on her studies and social life.
Between five and six weeks after treatment she felt more
energized, especially in short-lasting bursts. Myalgic pain
was slightly improved, resulting in reduction in paraceta-
mol usage. The diarrhoea terminated. She had less fatigue
after special occasions with exertion, but did not experi-
ence significantly increased energy in daily life and did
not manage to increase efforts at school. From 13 weeks
after infusion she had stable CFS symptoms, only slightly
better than at baseline (Figure 1).
Then, from 26 weeks after the infusion, she experienced a
dramatic recovery of all CFS symptoms over the next few
weeks. Fatigue improved to the extent that she could par-
ticipate fully in school education, she resumed social life,
started more extensive physical exertion including jogging
and needed no rest during daytime. All muscle pain van-
ished, she had better appetite, stools normalized, and she
also had regular menstrual cycles for the first time in 7
years. Concentration ability and memory improved sub-
stantially. There were no other interventions that could
explain her symptom recovery. This major CFS improve-
ment lasted from 6 months until 10 1/2 months after
rituximab infusion. She then experienced gradual symp-
tom worsening over the next 4 weeks, with increasing
muscle pain, relapse of fatigue, cognitive dysfunction and
loose stools. She was then (48 weeks after the first rituxi-
mab) treated with two infusions of rituximab (500 mg/
m2) given two weeks apart (Figure 1). At this time point B-
lymphocytes in peripheral blood had recovered. From 5
weeks after the second rituximab treatment, she again
experienced short bursts of being energized, and from 10
weeks she had slight improvement of muscle pain and
cognitive function. Almost identical to the symptom
course after her first intervention, from approximately 5
months after the second (double) rituximab treatment
she experienced a dramatic response on all CFS symp-
toms, to the same extent as described above (Figure 1).
Toxicity
No acute toxicity was seen. Patients 1 had two, and patient
2 one uncomplicated upper respiratory tract infection, all
appearing approximately two months after one of the
rituximab treatments. Patient 1 had an episode of local-
ized herpes zoster 21 weeks after the first rituximab infu-
sion. No other toxicity was noticed during follow-up.
Discussion and conclusion
This case series of B-cell depletion was initiated after an
original clinical observation of unexpected and markedly
improved CFS symptoms in a patient treated for Hodg-
kin's disease with the MIME chemotherapy regimen. We
speculated that the initial observed effect was related to
Mtx, which is given in moderate doses in the MIME regi-
men (30 mg/m2/3 weeks, comparable to weekly doses
used in the treatment of connective tissue diseases (5–15
mg/m2/week). We postulated that a main mechanism
inducing the symptoms in CFS is a deregulation of the
immune system involving B-lymphocytes directly or indi-
rectly. B-cell depletion was induced with an anti-CD20
monoclonal antibody, as is standard practice with few
side effects in patients with B-cell lymphomas, rheuma-
toid arthritis and related connective tissue diseases
[15,16].
There were no clinical indications that the development of
Hodgkin's lymphoma in patient 1 (after six years of stable
CFS), or of testicular seminoma in patient 2 (after five
years of stable CFS), caused their fatigue symptoms. As
premedication before rituximab treatment, the patients
were given a single dose of dexamethasone 8 mg orally. It
is highly unlikely that this medication should influence
the symptom courses reported, as no significant improve-
ments were seen before at least six weeks follow-up.
All three patients, with 7–10 years of CFS disease dura-
tion, had substantial relief of all symptoms related to CFS
after rituximab intervention. Patients 1 and 2 had a
marked symptom improvement from approximately 6 to
12–16 weeks, thereafter slowly increasing symptoms (yet
still a benefit 6 months after treatment). Patient 3 had
slight symptom improvement from 6 to 26 weeks after
treatment, thereafter a major recovery of all symptoms
lasting until 40 weeks after treatment, followed by a grad-
ual worsening the following month. The clinical effect
achieved was significant with a major impact on quality ofBMC Neurology 2009, 9:28 http://www.biomedcentral.com/1471-2377/9/28
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life in all the three patients, assessed by the patients and
their families. However, the clinical improvements were
transient. Following retreatment with rituximab a similar
pattern of responses occurred in all three patients, how-
ever, of longer duration than at the first treatment
(patients 1 and 2). Patient 3 had again the impressive
response on all CFS symptoms approximately 5 months
after the second rituximab treatment, in line with the
course after her first intervention. Also, patient 1 had a
new substantial CFS symptom improvement starting from
10 weeks after start of weekly oral low-dose Mtx. In addi-
tion, patients 1 and 2 had a third course of rituximab
treatment, again with very similar initial major responses
as experienced in their previous interventions (however
with limited follow-up so far).
The mechanism behind the apparent effects of B-cell
depletion seen in this case series is not obvious. As in
rheumatoid arthritis [12], the improvement was delayed
in time compared to the rapid fall in blood B-cell counts.
Considering the time course of symptom relief with grad-
ual improvement starting six weeks after rituximab infu-
sion, and with also a late and major response in patient 3,
a plausible mechanistic explanation is reduced antibody
or autoantibody production by B-cell clones. It is worth
noting that patients 1 and 2 had other autoimmune dis-
eases (autoimmune thyroiditis and diabetes mellitus type
I, respectively) and may thus represent a particular subset
of CFS patients. Patient 3 had no history of autoimmune
disease. The kinetics of CFS symptom relapse could also
be compatible with an autoimmune mechanism. How-
ever, the relatively early symptom relapse starting 12–16
weeks after rituximab treatment in patient 1 and 2, at a
time point when CD19+ B-cells could not yet be detected
in peripheral blood, indicates that the target of a putative
autoimmune process is carefully regulated and present in
small amounts. In a study of rituximab treatment in
patients with rheumatoid arthritis, the B-cell levels did
not correlate with clinical response [17]. The kinetics of B-
cell return after rituximab treatment vary [18]. The pres-
ence of serum autoantibodies in CFS has been investi-
gated, with varying results [19-23]. In some studies, an
increase in proportion of CD20+ CD5+ B-cells has been
observed, an immunophenotype associated with autoan-
tibody-production [9,11]. Also, increased Th2-type
immune response seen in CFS might be associated with an
autoimmune mechanism [8]. The different roles of B-cells
in autoimmune diseases have recently been reviewed [24].
An autoimmune hypothesis could be supported by exper-
imental use of plasma exchange to eliminate putative
autoantibodies. To our knowledge, such data have not
been reported in the literature.
In a study, a subset of CFS patients harboured IgM anti-
bodies to either Epstein-Barr virus [14], or cytomegalovi-
rus [25], and were thought to have an ongoing viral
infection. This subset of CFS patients improved following
valacyclovir treatment [26]. In the present case series, the
three patients did not show evidence of ongoing infection
using standard serologic tests or PCR analyses during fol-
low-up. However, they all had mononucleosis prior to
CFS development and may thus represent a special subset
of CFS patients. As an alternative hypothesis, patients with
ongoing infection with a B-lymphotropic virus could per-
haps profit from B-cell lysis and depletion.
Among the most consistent immunological abnormalities
detected in CFS patients are T- and NK-cell dysfunctions
[10,27], and decreased intracellular perforin [28]. The B-
and T-cell functions are mutually related. B-cells produce
proinflammatory cytokines, they are regulators of other
effector cells in the immune system, and are efficient anti-
gen-presenting cells. Rituximab can therefore also exhibit
effects on T-cell mediated immunity, and also on NK-cell
and dendritic cell functions, see review [29]. Some pla-
cebo effect could be present in our study, although the
time course of symptom relief and worsening in all three
patients, suggests an objective effect on the underlying
mechanism of the disease. However, the need for a pla-
cebo control group when evaluating intervention in CFS
has been demonstrated [30]. Apart from one event of
localized and uncomplicated herpes zoster, no unex-
pected toxicity has occurred with 17–19 months follow-
up. Due to the still unknown aetiology of CFS, the toxicity
of B-cell depletion therapy is unknown. Toxicity data from
treatment of B-cell malignancies are extensive, while the
safety considerations in rheumatic diseases are being eval-
uated in long-term follow-up of patients enrolled in clin-
ical trials [31].
A remarkable feature of this case series is that all three
patients had improvement of all CFS related symptoms
following the B-cell depletion. One patient with sufficient
follow-up had response also to weekly, oral Mtx. This
indicates that a main mechanism of symptom develop-
ment is touched by the drug manipulation. We anticipate
that a subset of patients with CFS will benefit from anti-
CD20 B-cell depletion therapy. The tolerance to B-cell
depletion was good in our patients, based on 17 – 19
months follow-up.
In conclusion, this first report in the literature of B-cell
depleting therapy in CFS patients strongly suggests a clin-
ical benefit, and that B-cell depletion may be an effective
drug intervention for this common, disabling disease. B-
cell depletion therapy in CFS should thus be further
explored.BMC Neurology 2009, 9:28 http://www.biomedcentral.com/1471-2377/9/28
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